DeepMed Research

PF-08046037

Generic Name: PF-08046037

Clinical Trials

A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies

Phase 1

Not yet recruiting

Conditions: Carcinoma, Non Small Cell Lung
Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Carcinoma, Pancreatic Ductal
Malignant Melanoma

Interventions: Drug: PF-08046037
Drug: sasanlimab

First Posted Date: 2025-05-16

Last Posted Date: 2025-05-16

Lead Sponsor: Pfizer

Target Recruit Count: 399

Registration Number: NCT06974734

Locations: 🇺🇸
START Midwest, Grand Rapids, Michigan, United States

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy